media – Page 384 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

A high proportion of adults in Europe do not have protective antibody concentrations against diphtheria

In a recent study published in the Eurosurveillance Journal, researchers conducted a retrospective analysis of seroprotection against tetanus and diphtheria among residents in Austria following an increase in diphtheria cases since 2022 in Europe. Background Diphtheria is an infection caused by Corynebacterium diphtheriae resulting in the inflammation of mucous membranes in the throat and nose. While an increase in the incidence of diphtheria among migrants in Europe was observed beginning in August 2022, recent studies also found that the concentrations of antibodies against diphtheria in adults in approximately 18 countries in the European Union were negligible. Although no diphtheria outbreaks have been reported among the general population of European Union countries, the low seroprotection increases the risk of disease outbreaks. Estimating the seroprevalence among the population could help determine the risk of a diphtheria outbreak and increase awareness about the importance of vaccines to ensure ...
- Source: drugdu
- 151
- May 3, 2023
Johnson & Johnson consumer health unit valued at $40 billion ahead of IPO, report says

Johnson & Johnson’s consumer health business is valued at $40 billion ahead of its initial public offering later this year, according to a report by The Wall Street Journal. The soon-to-be spinoff Kenvue aims to raise $3.5 billion or more in the offering, people familiar with the matter told the Journal. The newspaper noted that “the share sale would be by far the biggest of what so far has been a quiet year for IPOs.” Kenvue plans to meet with prospective investors as early as Monday, the sources told the Journal. When asked about the Journal’s report, J&J spokesperson Tesia Williams told CNBC, “Unfortunately, I do not have any information to provide.” J&J previously said it expects to complete the separation from Kenvue by mid- to late 2023. The consumer staples giant has also said it will retain majority ownership of Kenvue, with ...
- Source: drugdu
- 155
- May 3, 2023
Excessive digital technology use is associated with reduced sleep quality regardless of environmental and genetic factors, study finds

In a recent study published in the SLEEP Journal, researchers explored the association between poor sleep and the excessive use of digital technology among adolescents after adjusting for familial factors and examining the influence of environmental and genetic factors on the association. Background Although many studies have reported that excessive use of digital technology among adolescents and young adults is linked to lower sleep quality, recent research indicates that in studies that used relevant control groups, the association was weaker or non-significant. This implied that a third unexplored factor, such as environmental or genetic influences, could be the underlying reason for these observed associations. Factors related to parental control and lack of boundaries resulting in inconsistent bedtimes and excessive use of technology could be impacting the quality of sleep. Digital technology is thought to impact sleep quality in various ways. Hyperarousal and the requirement to constantly ...
- Source: drugdu
- 131
- May 3, 2023
Jenny Craig tells staffers it’s winding down its weight-loss centers and warns of mass layoffs

Jenny Craig has alerted employees to potential mass layoffs as it begins “winding down physical operations” and hunts for a buyer, according to communications the weight-loss company sent some staffers this week. The company said it “has been going through a sales process for the last couple of months,” according to a document titled “Jenny Craig Company Transition FAQs” that was dated Tuesday and provided to NBC News. Several Jenny Craig staffers said the company alerted them in recent days about potential layoffs. The FAQ document said: “While we had to issue Warn Notices specifically for sites where we had more than 50 people potentially impacted, this will likely impact all employees in some manner. “We do not know the exact employees/groups whom will be impacted, and if any employees may be retained. As a result, we would suggest that you anticipate that your employment may ...
- Source: drugdu
- 116
- May 3, 2023
Amgen faces patent infringement claims on big-selling osteoporosis drug Evenity

In developing its osteoporosis drug Evenity more than a decade ago, it is alleged in court documents that Amgen discussed forming a potential partnership with a small company from Kansas. Those discussions never amounted to a deal. Now, 11 years later, the Kansas company is suing Amgen for patent infringement. The suit, filed in U.S. District Court in Massachusetts, claims Amgen’s Evenity infringes on three of patents owned by OssiFi-Mab, including one that was granted last month. The first patent was awarded in 2012, the same year that Amgen and the Kansas company talked of a potential collaboration, according to the suit. The patents refer to the “discovery of methods of increasing bone density via administration of a sclerostin antagonist together with an antiresorptive,” the complaint says. Evenity works in part by decreasing bone resorption by inhibiting the action of sclerostin, which helps regulate bone metabolism. ...
- Source: drugdu
- 122
- May 3, 2023
Johnson & Johnson’s PARP combo nabs first global nod but faces tough fight against AZ, Merck’s Lynparza

Johnson & Johnson’s idea to carve out the prostate cancer indication from GSK’s PARP inhibitor Zejula has yielded its first global approval. Following a recommendation from the European Medicines Agency, the European Commission has officially approved J&J’s Akeega in metastatic castration-resistant prostate cancer (mCRPC), J&J said Friday. The drug is a fixed-dose combo of Zejula and J&J’s androgen-directed Zytiga, and it’s used alongside a corticosteroid. Under a 2016 deal with Zejula’s developer Tesaro, J&J specifically carved out rights to the drug in prostate cancer. GSK then bought out Tesaro in 2019. Not all patients can get Akeega under the drug’s European label. To be eligible, a patient’s tumor must test positive for BRCA1/2 mutations, which account for 10% to 15% of all cases, J&J said. Akeega’s label in Europe is narrower than that of rival PARP inhibitor Lynparza from AstraZeneca and Merck. The European Commission in December cleared Lynparza and Zytiga for mCRPC ...
- Source: drugdu
- 124
- May 3, 2023
European paediatricians sound alarm over medicine shortage

Paediatricians from European countries have raised the alarm over a shortage of medicines for children including antibiotics and asthma treatment, warning it was endangering health. In a letter addressed to health ministers and seen by AFP on Saturday, the doctors stressed it was “urgent to find a fast, reliable and lasting solution” to the problems facing stocks in Europe. “The health of our children and our youngsters is in danger because of the lack of medicines throughout Europe,” they wrote. The letter was addressed to the health ministers of Austria, France, Germany, the Italian region of South Tyrol and Switzerland. It was co-signed notably by Andreas Werner, president of the French Association of Ambulatory Pediatrics, his German counterpart Thomas Fischbach and Laura Reali, head of the European Confederation of Primary Care Paediatricians. The doctors said it was the responsibility of political decision-makers to ...
- Source: drugdu
- 168
- May 2, 2023
WHO announces launch of new pandemic preparedness initiative

The guidance focuses on respiratory pathogens, including influenza and respiratory syncytial virus. The World Health Organization (WHO) has launched a new initiative to help countries better prepare for future pandemics. The new ‘Preparedness and Resilience for Emerging Threats Initiative’ incorporates the latest tools and approaches for shared learning and collective action established during the COVID-19 pandemic and other recent public health emergencies, according to WHO. The initiative’s first module focuses specifically on responding to the threat or arrival of respiratory pathogens, including influenza, COVID-19 and respiratory syncytial virus. This will enable countries to critically review, test and update their respiratory pandemic planning efforts to ensure they have the functional capacities and capabilities in place. A process is currently underway to identify the next group of pathogens, such as arboviruses, to be addressed under this initiative. Dr Tedros Adhanom Ghebreyesus, WHO director-general, said: “Preparedness, prevention, and ...
- Source: drugdu
- 155
- May 2, 2023
Pfizer CEO’s texts with European Commission chief trigger new NYT lawsuit

Twenty-two months after European Commission President Ursula von der Leyen admitted to The New York Times that she negotiated a COVID-19 vaccine deal with Pfizer CEO Albert Bourla, Ph.D., through text messages, the newspaper is suing the commission over its refusal to make the texts public. While the lawsuit was filed on Jan. 25 and listed on the European Court of Justice’s public website Monday, Feb. 13, none of the documents related to the case are available to the public. Two people familiar with the suit confirmed it to Politico. The NYT argues that the EC is required legally to turn over the messages. Last year—in response to a public information request—the commission wrote that text messages do not need to be stored because they are treated as “short-lived ephemeral documents.” Reference: https://www.politico.eu/article/new-york-times-sue-european-union-ursula-von-der-leyen-pfizer-texts/
- Source: drugdu
- 138
- May 2, 2023
Kite’s CAR-T therapies recommended by NICE for certain blood cancers

The two treatments could benefit up to 600 patients each year in England via the Cancer Drugs Fund. Kite – a Gilead company – has announced that two of its CAR T-cell therapies have been recommended by the National Institute for Health and Care Excellence (NICE) as options to treat certain aggressive blood cancers. The treatments, both given as one-off infusions, have been specifically recommended for use within the Cancer Drugs Fund (CDF), which pays for cancer treatments while further data is collected on their clinical effectiveness. Kite’s Yescarta (axicabtagene ciloleucel) has been recommended for adults with diffuse large B‑cell lymphoma (DLBCL) that returns within a year of, or is resistant to, first-line chemoimmunotherapy. It can also be used with a stem cell transplant in some cases. The treatment was previously available as standard care after two or more systemic therapies, with the updated guidance now making it available after ...
- Source: drugdu
- 145
- May 2, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.